



Asthma management through the ages

An expert guided timeline of the key
milestones in asthma research and management



Also available as a video featuring Professor Ian Pavord and Assistant Professor Simon Couillard discussing the key milestones in asthma research and management

CN-155451 | Jan 2025

Key milestones in asthma management



EpiCentral

UNDERSTANDING THE CENTRAL ROLE OF THE
EPITHELIUM IN SEVERE ASTHMA AND BEYOND

This document has been sponsored and developed by AstraZeneca. The content is intended for healthcare professionals only.

Navigational features of this document

Click on the following icons to:



Return to asthma era overview



Explore key reference sources



Navigate to next asthma era



See full reference list



Navigate to previous asthma era



Close pop up



Click for more information



Asthma management timeline: era overview*

To dive into the key milestones, click on the various eras:

An early era of asthma diagnosis and management based largely on patient symptoms...


'Prescientific' era

An era of asthma diagnosis and management based on key inflammatory markers...

'Immunological' era

An era of asthma diagnosis and management based on the discovery that specific asthma drivers can be targeted...

'Endotypes' era



'Physiological' era

An era of asthma diagnosis and management based on physiological measures, including spirometry and bronchodilation...

'Phenotypic' era

An era of asthma diagnosis and management based on the discovery that key asthma clusters can be mapped into phenotypes...

'Epithelial' era**


An era of asthma diagnosis using the increasing understanding of the role of the airway epithelium, and its potential in mediating asthma...

*Timeframes noted in the era overview are approximate date ranges for each era and further details are subsequently provided.

**The 'Epithelial' era is based on a current theoretical era of ongoing research focussed on the epithelium. The views and opinions are those of AstraZeneca and key opinion leaders involved in the creation of this document.

The 'Prescientific' era

❖ Traditionally, asthma was classified based on symptoms and clinical characteristics alone. Progress in asthma management was made in the 1800s, where a written definition of asthma was coined by Sir William Osler.



References. 1. History of asthma (part 1). 2017. <https://asthma.net/living/history-of-asthma-part-one-in-the-beginning> [Accessed August 2022]; 2. Kouri A, et al. Eur Respir Rev. 2021;30:210081; 3. Diamant Z, et al. Respir Med. 2007;101(3):378–388; 4. Valent P, et al. J Innate Immun. 2016;8:111–120; 5. Schwartz RS. N Engl J Med. 2004;350(11):1079–80; 6. Holgate ST. Allergy Asthma Immunol Res. 2010;2(3):165–71; 7. McFadden ER. Am J Respir Crit Care Med. 2004;170:215–221; 8. Rackemann FM. Arch Intern Med. 1918;12:517–552; 9. Rackemann FM. Am J Med. 1947;3(5):601–6.

The 'Prescientific' era

Traditionally, asthma was classified based on symptoms and clinical characteristics alone. Progress in asthma management was made in the 1800s, where

First use of the term 'Asthma'

The earliest text where the word *asthma* is found as a medical term is in the writings of the school of **Hippocrates** of Kos¹



Asthma derives from the Greek 'ασθμα', meaning a '*short-drawn breath, hard breathing, or death rattle*'²



Want to read more?

References. 1. Marketos SG and Ballas CN. J Asthma. 1982;19(4), 263–269; 2. Pavord ID, et al. Lancet. 2017;391(10118):350–400.



Scriptures from China and ancient Egypt describe **symptoms of breathlessness and respiratory distress**. 'Noisy breathing' or wheezing was recognised as signs of illness¹

Roman doctors describe **and the inability to breathe (wheezing)**. Connected with worsening symptoms, activity and that breathing difficult

Meltzer theorises that asthma in humans and anaphylaxis in guinea pigs are equivalent because they both involve the airways. **Asthma is no longer considered a neurosis**⁷

2,600 BCE

460 BC

50 AD

1892

1910

1918

Hippocrates is the first to use the term 'Asthma' as a panting and respiratory illness¹

William Osler as a **bes and swelling membranes, that never, begins in families**⁶

Francis Rackemann describes two clinical phenotypes of asthma; **extrinsic and intrinsic asthma**^{8,9}

Approximate time period: Pre 1930s


References. 1. History of asthma (Part 1). 2017. <https://asthma.net/living/history-of-asthma-part-one-in-the-beginning> [Accessed August 2022]; 2. Kouri A, et al. Eur Respir Rev. 2021;30:210081; 3. Diamant Z, et al. Respir Med. 2007;101(3):378–388; 4. Valent P, et al. J Innate Immun 2016;8:111–120; 5. Schwartz RS. N Engl J Med. 2004;350(11):1079–80; 6. History of asthma (part 2). 2017. <https://asthma.net/living/history-of-asthma-part-2-modern-history> [Accessed August 2022]; 7. McFadden ER. Am J Respir Crit Care Med. 2004;170:215–221; 8. Rackemann FM. Arch Intern Med 1918;12:517–552; 9. Rackemann FM. Am J Med. 1947;3(5):601-6.

Traditionally, asthma was classified based on symptoms and clinical characteristics alone. Progress in asthma management was made in

Paul Ehrlich, the eosinophil, and the 'magic bullet'

Ehrlich uses **dye-staining** to **differentiate and describe various leukocytes**, including the eosinophil¹⁻³

Ehrlich also develops the concept of a targeted drug informally named a '**magic bullet**' – a drug that would be specific for its target without affecting normal host cells¹⁻³



Want to read more?

References. 1. Valent P, et al. J Innate Immun. 2016;8:111–120; 2. Schwartz RS. N Engl J Med. 2004;350(11):1079–80; 3. Varricchi G, et al. Ther Adv Respir Dis. 2017;11(1):40–45.

Approximate time period: Pre 1930s


References. 1. History of asthma (Part 1). 2017. <https://asthma.net/living/history-of-asthma-part-one-in-the-beginning> [Accessed August 2022]; 2. Kouri A, et al. Eur Respir Rev. 2021;30:210081; 3. Diamant Z, et al. Respir Med. 2007;101(3):378–388; 4. Valent P, et al. J Innate Immun 2016;8:111–120; 5. Schwartz RS. N Engl J Med. 2004;350(11):1079–80; 6. History of asthma (part 2). 2017. <https://asthma.net/living/history-of-asthma-part-2-modern-history> [Accessed August 2022]; 7. McFadden ER. Am J Respir Crit Care Med. 2004;170:215–221; 8. Rackemann FM. Arch Intern Med 1918;12:517–552; 9. Rackemann FM. Am J Med. 1947;3(5):601-6.

Traditionally, asthma was classified based on symptoms and clinical characteristics alone. Progress in asthma management was made in the 19th century.

Asthma is a complex disease


Francis Rackemann highlights the **heterogeneity** of asthma.¹ He distinguishes between **asthma subtypes** based on various observations, including family history, eosinophilia, and treatment^{1,2}

Intrinsic asthma



- Due to factors **intrinsic to the body**
- Associated with **older age at onset**
- Unlikely to be atopy

Extrinsic asthma



- Due to **allergens from outside the body**
- Associated with **younger age of onset**
- Presence of **atopy and other allergic diseases**
- **Environmental triggers**



Want to read more?

References. 1. Rackemann FM. Arch Intern Med. 1918;12:517–552; 2. Rackemann FM. Am J Med. 1947;3(5):601–6.

References. 1. History of asthma (Part 1). 2017. <https://asthma.net/living/history-of-asthma-part-one-in-the-beginning> [Accessed August 2022]; 2. Kouri A, et al. Eur Respir Rev. 2021;30:210081; 3. Diamant Z, et al. Respir Med. 2007;101(3):378–388; 4. Valent P, et al. J Innate Immun. 2016;8:111–120; 5. Schwartz RS. N Engl J Med. 2004;350(11):1079–80; 6. History of asthma (part 2). 2017. <https://asthma.net/living/history-of-asthma-part-2-modern-history> [Accessed August 2022]; 7. McFadden ER. Am J Respir Crit Care Med. 2004;170:215–221; 8. Rackemann FM. Arch Intern Med. 1918;12:517–552; 9. Rackemann FM. Am J Med. 1947;3(5):601–6.

The 'Physiological' era

- ❖ The physiological era saw a move away from symptoms. During this era, asthma was considered as an acute disorder of episodic exacerbations, as a result of dysregulated airway neural control rather than a chronic inflammatory process.

Quantification of responses to nebulised epinephrine in asthma is reported - the first publication on the **effectiveness of bronchodilation** for patients with asthma and emphysema¹

Two French physicians, Robert Tiffeneau and André Pinelli, establish the concept of **forced expiratory volume** in one second (FEV₁) and introduce the **FEV₁/FVC ratio**¹

Sputum eosinophilia found to determine the response to oral and inhaled corticosteroids – **drawing attention to the role of eosinophils in asthma**^{5,6}

Inhaled corticosteroids are tested in multiple clinical trials for their efficacy in asthma management. The discovery that they can reduce airway eosinophilic, mast cell and inflammation provides evidence for their efficacy in controlling day-to-day asthma⁸

1930s

1946

1947

1956

1958

1966

1970s

1979

Bronchial hyperresponsiveness characteristics of asthma are first described by John Curry^{2,3}

The results from a Medical Research Council **trial for the use of corticosteroids for asthma attacks** are reported⁴

Discovery of IgE and its role in mast cell activation⁷

The American Thoracic Society publish the first US **standardised guidelines for spirometry** followed by the European guidelines in 1983¹

Approximate time period: 1930s–1970s

Abbreviations. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; IgE, immunoglobulin E; US, United States.

References. 1. Kouri A, et al. Eur Respir Rev. 2021;30:210081; 2. McFadden ER. Am J Respir Crit Care Med. 2004;170:215–221; 3. Curry JJ. J Clin Invest. 1946;25(6):785–791; 4. Medical Research Council (MRC). Lancet. 1956;271(6947):803–806; 5. Brown HM. Lancet. 1958;272 (7059):1245–1247; 6. Rupani H, et al. J Inflamm Res. 2021;14:4371–4397; 7. Diamant Z, et al. Respir Med. 2007;101(3):378–388; 8. Holgate ST. Allergy Asthma Immunol Res. 2010;2(3):165–71.

Key milestones in asthma management

The physiological era saw a move away from symptoms. During this era, asthma was considered as an acute disorder of episodic exacerbation.

The first report quantifying the effective use of a bronchodilator

In 1938, **Alvan Barach** notes diminished expiratory flow rates in adults with asthma and observes complete or partial reversal of these abnormalities with inhalation of nebulised epinephrine^{1,2}



Increase in
inspiratory velocity¹



Increase in
expiratory velocity¹



Slight increase in
vital capacity¹



Want to read more?

References. 1. Barach AL. Ann Intern Med. 1938;12(4):454–81; 2. Wu TD, et al. The history of pulmonary function testing. In: Kaminsky DA, Irvin CG, eds. Pulmonary Function Testing. Principles and Practice. Basel, Springer International Publishing, 2018;15–42.

Abbreviations. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; IgE, immunoglobulin E; US, United States.

References. 1. Kouri A, et al. Eur Respir Rev. 2021;30:210081; 2. McFadden ER. Am J Respir Crit Care Med. 2004;170:215–221; 3. Curry JJ. J Clin Invest. 1946;25(6):785–791; 4. Medical Research Council (MRC). Lancet 1956;271(6947):803–806; 5. Brown HM. Lancet. 1958;272 (7059):1245–1247; 6. Diamant Z, et al. Respir Med. 2007;101(3):378–388; 7. Holgate ST. Allergy Asthma Immunol Res 2010;2(3).


The 'Physiological' era

The physiological era saw a move away from symptoms. During this era, asthma was considered as an acute disorder of episodic exacerbation.

Efficacy of corticosteroids for asthmatic patients?


In the 1950s, the introduction of systemic corticosteroid treatment in the UK is not straightforward due to an early and influential clinical trial sponsored by the **Medical Research Council** showing **little efficacy and highlighting a high potential for systemic toxicity**.^{1,2}

During the three-month post-trial observation period:



9 out of 11
patients

in the **treatment group** reported having further attacks



7 out of 14
patients

in the **placebo group** reported having further attacks



[Want to read more?](#)

References. 1. Medical Research Council (MRC). Lancet. 1956;271(6947):803–806; 2. Pavord ID, et al. Lancet. 2017;391(10118):350–400.



The physiological era saw a move away from symptoms. During this era, asthma was considered as an acute disorder of episodic exacerbation.

Linking sputum eosinophilia with patient treatment response

Challenging the MRC trial, **Harry Morrow Brown** discovers that the **presence of eosinophils in the sputum** aligns with the **patients' response to corticosteroids**^{1,2}

90 cases of chronic asthma treated with corticosteroids¹

| Relief of bronchospasm | Cases with eosinophilic sputum | Cases with a few or no eosinophils |
|------------------------|--------------------------------|------------------------------------|
| Complete | 56 | 1 |
| Partial | 7 | 3 |
| Slight | - | 7 |
| No relief | - | 16 |
| Total | 63 | 27 |



In this study, **100%** of patients with **eosinophilic sputum** had **complete or partial relief**



Want to read more?


References. 1. Brown HM. Lancet. 1958;272 (7059):1245–1247; 2. Pavord ID, et al. Lancet. 2017;391(10118):350–400.

Abbreviations. FEV₁, forced expiratory volume in one second; FVC, forced vital capacity; IgE, immunoglobulin E; US, United States.

References. 1. Kouri A, et al. Eur Respir Rev. 2021;30:210081; 2. McFadden ER. Am J Respir Crit Care Med. 2004;170:215–221; 3. Curry JJ. J Clin Invest. 1946;25(6):785–791; 4. Medical Research Council (MRC). Lancet 1956;271(6947):803–806; 5. Brown HM. Lancet. 1958;272 (7059):1245–1247; 6. Diamant Z, et al. Respir Med. 2007;101(3):378–388; 7. Holgate ST. Allergy Asthma Immunol Res 2010;2(3).

The 'Immunological' era

- ❖ This era saw the understanding of the inflammatory and immunologic nature of asthma grow, alongside awareness that chronic asthma could lead to airway remodelling identifiable with spirometry.



Abbreviations. IL, interleukin.

References. 1. Holgate ST. Allergy Asthma Immunol Res. 2010;2(3):165-71; 2. Yokota T, et al. Proc Natl Acad Sci USA. 1986;83(16):5894-5898; 3. Azuma C, et al. Nucleic Acids Res. 1986;14(22):9149-9158; 4. Diamant Z, et al. Respir Med. 2007;101(3):378-388; 5. Pin I et al. Thorax. 1992;47:25-9; 6. Minty A, et al. Nature. 1993;362(6417):248-250; 7. Medzhitov R, et al. Nature. 1997;388(6640):394-397; 8. Pavord ID, et al. Lancet. 1999;353(9171):2213-2214; 9. Wenzel SE, et al. Am J Respir Crit Care Med. 1999;160(3):1001-8.

❖ This era saw the understanding of the inflammatory and immunologic nature of asthma grow, alongside a


Non-invasive measurement of airway inflammation

In the 1980s, the importance of persistent airway inflammation in the pathogenesis of asthma is becoming apparent. However, the type of inflammatory response is difficult to measure, with invasive methods required¹



Isabelle Pin *et al.* develops a non-invasive measurement of airway inflammation in asthmatic patients using induced sputum cell counts²

Differential cell counts of eosinophils and metachromatic cells in normal (n=17) and asthmatic subjects (n=17)



Adapted from Pin I et al. Thorax 1992;47:25-9.

Approximate time

Abbreviations. IL, interleukin
References. 1. Holgate ST, et al. Respir Med. 2007;101(10):1411-1418; 2. Pin I et al. Thorax. 1992;47:25-9.



Want to read more?

References. 1. Kirby JG, et al. Am Rev Respir Dis. 1987;136:379-83; 2. Pin I et al. Thorax. 1992;47:25-9.

❖ This era saw the understanding of the inflammatory and immunologic nature of asthma grow, alongside advances in the management of asthma.

Eosinophilic asthma vs. non-eosinophilic asthma

Two independent studies suggest that patients with severe asthma can be divided into **two distinct subgroups** based on the **presence or absence of eosinophils**^{1,2}

- **Ian Pavord *et al.*** show that patients with **non-eosinophilic asthma** have a **poor response to corticosteroids** compared to those with eosinophilic asthma¹
- **Sally Wenzel *et al.*** observe **distinct characteristics** of two pathologically different inflammatory groups of patients with **severe asthma** based on the **presence or absence of eosinophils**²

Non-eosinophilic asthma

| | |
|-------------------------|--|
| Definition | Absence of elevated eosinophil counts in blood or sputum (<3%) |
| Steroid response | Poor response to corticosteroids |

Eosinophilic asthma

| | |
|-------------------------|--|
| Definition | Increased blood (>300/ μ L) or sputum eosinophil counts (\geq 3%) |
| Steroid response | Good respond to corticosteroids |




Want to read more?

References. 1 Pavord ID, et al. *Lancet*. 1999;353(9171):2213–2214; 2. Wenzel SE, et al. *Am J Respir Crit Care Med*. 1999;160(3):1001–8.

Abbreviations. IL, interleukin
References. 1. Holgate ST, Alcock
et al. *Respir Med*. 2007;101(3):
1999;353(9171):2213–2214; 9. Wenzel SE, et al. *Am J Respir Crit Care Med*. 1999;160(3):1001–8.

The 'Phenotypic' era

- ❖ This era saw the clustering of specific asthma phenotypes based on observable characteristics resulting from a combination of both environmental and hereditary influences.




Abbreviations. ILC, innate lymphoid cell; Th, T helper cell; TSLP; thymic stromal lymphopoietin.

References. 1. Reche PA et al, J Immunol. 2001;167(1):336–343; 2. Green RH, et al. Lancet. 2002;360(9347):1715–1721; 3. Pavord ID, et al. Eur Respir Rev. 2019;28:190054; 4. Castillo JR, et al. J Allergy Clin Immunol. 2017;594):918–927.; 5. Miranda C, et al. J Allergy Clin Immunol. 2004;113(1):101–8; 6. West EE, et al. Drug Discov Today Dis Mech. 2012;9(3-4):10.1016/j.ddmec.2012.09.003; 7. Haldar P, et al. Am J Respir Crit Care Med. 2008;178(3):218–224; 8. Woodruff PG, et al. Am J Respir Crit Care Med. 2009;180(5):388–95; 9. Haldar P, et al. N Engl J Med. 2009;360:973-84; 10. Moore WC, et al. Am J Respir Crit Care Med. 2010;181(4):315–323; 11. Halim T. Int Immunol. 2016;28(1):13–22.

❖ This era saw the clustering of specific asthma phenotypes based on observable characteristics resulting from a combination of both environmental and genetic factors.

Targeting eosinophilic inflammation to reduce asthma exacerbations

Ruth Green *et al.* discovers that by managing patients using the induced sputum eosinophil count vs. standard management strategies:^{1*}



Lower sputum eosinophil count over 12 months (p=0.002)



Patients experience significantly fewer exacerbations (p=0.01)



Fewer patients are admitted to hospital with asthma (p=0.047)



Want to read more?

Abbreviations. BTS, British Thoracic Society.

References. 1. Green RH, et al. *Lancet*. 2002;360(9347):1715–1721.

*Patients (n=74) were randomised to receive standard management (BTS group) or management by normalisation of the induced sputum eosinophil count and reduction of symptoms (sputum group).


❖ This era saw the clustering of specific asthma phenotypes based on observable characteristics resulting from a combination of both environmental and genetic factors

Identifying clinical phenotypes

Pranab Haldar *et al.* identifies clinical phenotypes using cluster analysis in asthmatic populations¹

These can be plotted according to two clinically-pertinent and modifiable dimensions of asthma:¹

- **Relative expression of symptoms**
- **Eosinophilic inflammation**



Adapted from Haldar P, et al. Am J Respir Crit Care Med. 2008;178(3):218–224.



Want to read more?

References. 1. Haldar P, et al. Am J Respir Crit Care Med. 2008;178(3):218–224.

❖ This era saw the clustering of specific asthma phenotypes based on observable characteristics resulting from a combination of both environmental and genetic factors

Asthma phenotyping based on Th2 inflammation

Woodruff et al. show that asthma can be divided into **two distinct molecular phenotypes** defined by the degree of Th2 inflammation¹

Prescott Woodruff et al. observes that the patient subgroups (right) **differ significantly** (all $p < 0.03$) in:¹

- Expression of IL-5 and IL-13
- Airway hyperresponsiveness
- Serum IgE
- Blood and airway eosinophilia
- Subepithelial fibrosis
- Airway mucin gene expression



Want to read more?

Abbreviations: IgE, immunoglobulin E; IL, interleukin; ILC, innate lymphoid cell; Th, T helper cell.

References. 1. Woodruff PG, et al. Am J Respir Crit Care Med. 2009;180(5):388–95.

T2-High



- Allergic, atopic
- **Eosinophilic**
- **Steroid responsive**
- Involve Th2 and ILC2 cells

T2-Low



- Non-atopic
- **Non-eosinophilic**
- **Poor steroid response**
- Involve Th1 and Th17 cells



Distinct asthma
cluster analysis in
research program

Studies characterise ILC2 cells¹¹

Description of human TS

2001

Normalisation of
count found to be
and hospital adm
additional anti-in


Approximate time

Abbreviations. ILC, innate lymphoid cell; Th, T helper cell.
References. 1. Roche PA et al. Am J Respir Crit Care Med. 2017;195(2):184–90; 5. Miranville S et al. Am J Respir Crit Care Med. 2008;178(3):218–224; 8. Woodruff PG et al. Am J Respir Crit Care Med. 2009;180(5):388–95; 11. Halim T. Int Immunol. 2016;28(1):13–22.

Key milestones in asthma management

The 'Endotypes' era

- ❖ This era saw an evolution of asthma classification, via evaluation of the molecular mechanisms that drive a particular asthma phenotype. Asthma endotypes describe the specific pathophysiological mechanisms that drive asthma at a cellular level.



Abbreviations. ATS, American Thoracic Society; COPD, chronic obstructive pulmonary disease; ERS, European Respiratory Society; FDA, Food and Drug Administration; FeNO, fractional exhaled nitric oxide; NIH, National Institute of Health; U-BIOPRED, Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes.

References. 1. Porpodis K, et al. *J Pers Med.* 2022;12:1093; 2. Lötvall J, et al. *J Allergy Clin Immunol.* 2011;127(2):355–360; 3. Baines KJ, et al. *J Allergy Clin Immunol.* 2011;127:153–160; 4. Wenzel SE. *Nat Med.* 2012;18:716–725; 5. Price DB, et al. *Lancet Respir Med.* 2015;3(11):849–858; 6. Bafadhel M, et al. *Am J Respir Crit Care Med.* 2011;184:662–71; 7. Bafadhel M, et al. *Am J Respir Crit Care Med.* 2012;186:48–55; 8. Bafadhel M, et al. *Eur Respir J.* 2014;44:789–91; 9. Agusti A, et al. *Eur Respir J.* 2016;47:410–419; 10. Pavord ID, et al. *Lancet.* 2017;391(10118):350–400.

This era saw an evolution of asthma classification, via evaluation of the molecular mechanisms that drive a particular asthma



Linking biology to phenotypes – suggesting categories of asthma

Asthma phenotypes initially focused on combinations of clinical characteristics, but evolve to link biology to phenotype (i.e., endotype)¹

| | Clinical features | Pathobiology and biomarkers |
|-------------------------|---|---|
| Early-onset allergic | Allergic symptoms; mild to severe | Specific IgE; Th2 cytokines; thick SBM |
| Late-onset eosinophilic | Sinusitis; less allergic; often severe | Corticosteroid-refractory eosinophilia; IL-5 |
| Exercise-induced | Mild; intermittent with exercise | Mast-cell activation; Th2 cytokines; cysteinyl leukotrienes |
| Obesity-related | Symptomatic; airway hyperresponsiveness unclear | Lack of Th2 biomarkers; oxidative stress |
| Neutrophilic | Low FEV ₁ ; more air trapping | Sputum neutrophilia; Th17 pathways; IL-8 |

Sally Wenzel highlights that future molecular and genetic-focused research may enhance our understanding of asthma phenotypes and lead to more targeted and personalised approaches to asthma therapy¹



Want to read more?



Abbreviations. FEV₁, forced expiratory volume per second; IgE, immunoglobulin E; IL, interleukin; ILC, innate lymphoid cell; SBM, subepithelial basement membrane; Th, T helper cell.

References. 1. Wenzel SE. Nat Med. 2012;18:716–725.


This era saw an evolution of asthma classification, via evaluation of the molecular mechanisms that drive a particular asthma




Using blood eosinophil count as a predicative biomarker

Studies in patients with COPD highlight that patients who present in similar ways can have considerable differences in their airway inflammation.^{1,2} Additionally, these studies suggest that the heterogeneity seen with COPD patients can be defined using readily accessible biomarkers, such as blood eosinophil counts¹⁻⁴

In the setting of an exacerbation **Mona Bafadhel *et al.*** show that **blood eosinophil counts** help identify patients with COPD who may **respond better to oral steroids**⁴



treatment failure rate in patients with a **blood eosinophil count $\geq 2\%$** , who do not receive oral steroids vs. those who do.



treatment failure rate in patients with a **blood eosinophil count $< 2\%$** , who do not receive oral steroids vs. those who do.

*Mean difference 55%, 95% CI 38–73%, $p < 0.001$.⁴

**Mean difference 6%, 95% CI -9–27%, $p = \text{ns}$.⁴

Want to read more?



Abbreviations. COPD, chronic obstructive pulmonary disorder; ns, not significant.

References. 1. Pavord ID, et al. *Lancet*. 2017;391(10118):350–400; 2. Bafadhel M, et al. *Am J Respir Crit Care Med*. 2011;184:662–71; 3. Bafadhel M, et al. *Am J Respir Crit Care Med*. 2012;186:48–55; 4. Bafadhel M, et al. *Eur Respir J*. 2014; 44: 789–91.

The 'Endotypes' era

This era saw an evolution of asthma classification, via evaluation of the molecular mechanisms that drive a particular asthma

Call for a new 'standard' approach to asthma management and treatment focusing on precision medicine

In a Lancet Commission, **expert clinicians and researchers** in asthma provide their view of where we are and where we need to go as a community to tackle the considerable public health problem of asthma¹



Want to read more?

References. 1. Pavord ID, et al. Lancet. 2017;391(10118):350–400.

Seven key recommendations from the Commission are:¹



A revolution in delivering precision medicine in asthma treatment



Emerge from the age-associated and discipline-associated silos



Zero tolerance for attacks



Better research



Test before treatment



Move beyond a disease control approach towards prevention and disease modifying treatments




Make the most of new opportunities in severe disease



The 'Epithelial' era*

❖ Epithelial science is a new frontier in asthma research, and we are working to better characterise the key role of the airway epithelium and epithelial cytokines – such as thymic stromal lymphopoietin (TSLP), interleukin (IL)-33 and IL-25 – in triggering inflammation in asthma.



*The 'Epithelial' era is based on a current theoretical era of ongoing research focussed on the epithelium. The views and opinions are those of AstraZeneca and key opinion leaders involved in the creation of this document.

Abbreviations. FeNO, fractional exhaled nitric oxide; RNA, ribonucleic acid.

References. 1. Hunninghake GM, et al. *Allergy*. 2010; 65:1566–1575; 2. Moffatt MF, et al. *N Engl J Med*. 2010; 363:1211–1221; 3. Torgerson DG, et al. *Nat Genet*. 2011; 43:887–892; 4. Holgate ST. *Immunol Rev*. 2011;242:205–219; 5. Heijink IH, et al. *Clin Exp Allergy*. 2014;44(5):620-630; 6. Li X, et al. *Allergy*. 2015;70(10):1309–1318; 7. Plasschaert LW, et al. *Nature*. 2018;560(7718):377–38; 8. Couillard S, et al. *Am J Respir Crit Care Med*. 2021;204:731–4; 9. Couillard S, et al. *ERJ Open Res*. 2021;8(1):00570-2021; 10. Couillard S, et al. *Thorax*. 2022;77(2):199-202 11. Couillard S, et al. *Respirology*. 2022;27:573–574; 12. Heijink IH, et al. *Eur J Allergy Clin Immunol*. 2020;75(8):1902–1917.

Key milestones in asthma management



Epithelial science is a new frontier in asthma research, and we are working to better characterise the key role of the airway

Linking FeNO and blood eosinophils to different compartments of inflammation

Simon Couillard *et al.* uncover a relationship between fractional exhaled nitric oxide (FeNO), blood eosinophils, and various biomarkers of airway-specific and systemic inflammation including alarmins, chemokines and cytokines¹


These findings imply that **FeNO** and **blood eosinophils** relate to **different components** and **compartments of type 2 inflammation**¹



Want to read more?


References. 1. Couillard S, et al. Am J Respir Crit Care Med. 2021;204:731–4.

*The 'Epithelial' era is based on a current theoretical era of ongoing research focussed on the epithelium. The views and opinions are those of AstraZeneca and key opinion leaders involved in the creation of this document.



FeNO reflects airway type 2 activity and the chemotactic pull in the epithelium

AND




Blood eosinophils reflect the systemic pool of available effector cells and circulating IL-5

Epithelial science is a new frontier in asthma research, and we are working to better characterise the key role of the airway



Predicting the risk of asthma attacks with two biomarkers from different compartments: FeNO and blood eosinophil count

Using biomarker-stratified attack rates from the control arms of several clinical trials (n=3051), **Simon Couillard *et al.*** proposes the **prototype Oxford Asthma Attack Risk Scale (ORACLE)** that shows potential to **predict asthma attacks** based on **blood eosinophil count and FeNO**^{1,2}



Want to read more?

Abbreviations. FeNO, fractional exhaled nitric oxide.

References. 1. Couillard S, et al. Thorax. 2022;77(2):199–202; 2. Couillard S, et al. ERJ Open Res. 2022;8(1):00570–2021.

*The 'Epithelial' era is based on a current theoretical era of ongoing research focussed on the epithelium. The views and opinions are those of AstraZeneca and key opinion leaders involved in the creation of this document.

Adapted from Couillard S, et al. Thorax. 2022;77(2):199–202.




Epithelial science is a new frontier in asthma research, and we are working to better characterise the key role of the airway



A 'bomb' (blood eosinophils) meets a 'magnet' (FeNO)¹

Simon Couillard *et al.* outline potential features of 'magnet' and 'bomb' patients with Th2-high asthma:¹



Adapted from Couillard S, et al. *Respirology*. 2022;27(8):573-577.

This may lead to the possibility for **precision medicine**, and the selecting of the most appropriate treatment based on the patient 'magnet'/'bomb' biomarker profiles¹



Want to read more?

Abbreviations. AhR, airway hyperresponsiveness; CRSwNP, chronic rhinosinusitis with nasal polyps; EGPA, eosinophilic granulomatosis with polyangiitis; FeNO, fractional exhaled nitric oxide; Th, T helper cell.

References. 1. Couillard S, et al. *Respirology*. 2022;27(8):573-577.

*The 'Epithelial' era is based on a current theoretical era of ongoing research focussed on the epithelium. The views and opinions are those of AstraZeneca and key opinion leaders involved in the creation of this document.



Epithelial science is a new frontier in asthma research, and we are working to better characterise the key role of the airway

Further insights into asthma and role of the epithelium may come from technology advances

Abnormalities in the airway epithelial barrier play a crucial role in the sensitisation to allergens and **pathogenesis of asthma**¹

The exact mechanisms by which the expression of epithelial susceptibility genes translates into a functionally altered response to environmental risk factors of asthma are still unknown¹

Insight into the epithelial barrier in asthma using **single cell RNA sequencing (scRNA-seq)** holds promise for identifying patients likely to benefit from **epithelial-focused therapies** and the finding **targets for novel therapies** aimed at correcting dysfunctional epithelial barrier¹




Want to read more?

Abbreviations. RNA, ribonucleic acid.

References. 1. Heijink IH, et al. Eur J Allergy Clin Immunol. 2020;75(8):1902–1917.

*The 'Epithelial' era is based on a current theoretical era of ongoing research focussed on the epithelium. The views and opinions are those of AstraZeneca and key opinion leaders involved in the creation of this document.





Key reference sources (1/2)

To read more about some of the key milestones in the asthma timeline, click the citation below:

Pre-scientific era

1. [Marketos SG & Ballas CN. J Asthma. 1982;19\(4\);263–269](#)
The origin of the term asthma in Greek literature
2. [Valent P, et al. J Innate Immun. 2016;8:111–120](#)
Paul Ehrlich's contributions to science including cell staining and the concept of magic bullets
3. [Rackemann FM. Arch Intern Med. 1918;12:517–552](#)
First publication that establishes the terms intrinsic and extrinsic asthma
4. [Rackemann FM. Am J Med. 1947;3\(5\):601–6](#)
Further classification of intrinsic and extrinsic asthma

Physiological era

1. [Medical Research Council \(MRC\). Lancet. 1956;271\(6947\):803–806](#)
Results of the MRC trial investigating the use of corticosteroids for patients with asthma
2. [Brown HM. Lancet. 1958;272 \(7059\):1245–1247](#)
This study highlights the link between eosinophilic sputum and the patient response to treatment
3. [Rupani H, et al. J Inflamm Res. 2021;14:4371–4397](#)
This review discusses the recent insights into the management of inflammation in asthma

Immunological era

1. [Pin I et al. Thorax. 1992;47:25–9](#)
Isabelle Pin's study on the use of induced sputum cell counts to investigate airway inflammation in asthma
2. [Pavord ID, et al. Lancet. 1999;353\(9171\):2213–2214](#)
This study highlights different treatment responses depending on the presence of eosinophilic airway inflammation
3. [Wenzel SE, et al. Am J Respir Crit Care Med. 1999;160\(3\):1001–8](#)
This study establishes various characteristics of non-eosinophilic and eosinophilic asthma



Key reference sources (2/2)

To read more about some of the key milestones in the asthma timeline, click the citation below:

Phenotypic era

1. [Green RH, et al. Lancet. 2002;360\(9347\):1715–1721](#)
This study discusses the positive impact of managing patients using the induced sputum eosinophil count
2. [Haldar P, et al. Am J Respir Crit Care Med. 2008;178\(3\):218–224](#)
This study identifies clinical phenotypes using cluster analysis in asthmatic populations
3. [Woodruff PG, et al. Am J Respir Crit Care Med. 2009;180\(5\):388–95](#)
This study highlights two distinct molecular phenotypes defined by Th2 (low or high) inflammation

Endotype era

1. [Wenzel SE. Nat Med. 2012;18:716–725](#)
This review outlines various categories of asthma that begin to link phenotypes to the underpinning biology (i.e. endotypes)
2. [Bafadhel M, et al. Eur Respir J. 2014; 44: 789–91](#)
This study highlights the use of the blood eosinophil count to possibly identify patient treatment responses
3. [Pavord ID, et al. Lancet. 2017;391\(10118\):350–400](#)
This Commission provides a detailed expert view of the current and future landscape of asthma

Epithelial era*

1. [Couillard S, et al. Am J Respir Crit Care Med. 2021;204:731–4](#)
This study connects FeNO and blood eosinophils with biomarkers and compartments of airway inflammation
2. [Couillard S, et al. Thorax. 2022;77\(2\):199-202](#)
This study outlines a proposed prototype risk scale (ORACLE) to predict asthma attacks
3. [Couillard S, et al. ERJ Open Res. 2021;8\(1\):00570-2021](#)
This study suggests a potential theragnostic utility of the ORACLE scale using trial-level data
4. [Couillard S, et al. Respirology. 2022;27\(8\):573-577](#)
This commentary details a sub-stratification of asthma based on ‘bombs’ (blood eosinophils) and ‘magnets’ (FeNO)
5. [Heijink IH, et al. Eur J Allergy Clin Immunol. 2020;75\(8\):1902–1917](#)
This review focusses on insights and future research into the role of the airway epithelium in asthma

*The ‘Epithelial’ era is based on a current theoretical era of ongoing research focussed on the epithelium. The views and opinions are those of AstraZeneca and key opinion leaders involved in the creation of this document.



References (1/2)

- ❁ History of asthma (part 1). 2017. <https://asthma.net/living/history-of-asthma-part-one-in-the-beginning> [Accessed August 2022].
- ❁ Kouri A, et al. *Eur Respir Rev.* 2021;30:210081.
- ❁ Diamant Z, et al. *Respir Med.* 2007;101(3):378–388.
- ❁ Valent P, et al. *J Innate Immun.* 2016;8:111–120.
- ❁ Schwartz RS. *N Engl J Med.* 2004;350(11):1079–80.
- ❁ Holgate ST. *Allergy Asthma Immunol Res.* 2010;2(3):165–71.
- ❁ McFadden ER. *Am J Respir Crit Care Med.* 2004;170:215–221.
- ❁ Rackemann FM. *Arch Intern Med.* 1918;12:517–552.
- ❁ Rackemann FM. *Am J Med.* 1947;3(5):601–6.
- ❁ Marketos SG and Ballas CN. *J Asthma.* 1982;19(4), 263–269.
- ❁ Pavord I, et al. *Lancet.* 2017;391(10118):350–400.
- ❁ Varricchi G, et al. *Ther Adv Respir Dis.* 2017;11(1):40–45.
- ❁ Curry JJ. *J Clin Invest.* 1946;25(6):785–791.
- ❁ Medical Research Council (MRC). *Lancet.* 1956;271(6947):803–806.
- ❁ Brown HM. *Lancet.* 1958;272(7059):1245–1247.
- ❁ Rupani H, et al. *J Inflamm Res.* 2021;14:4371–4397.
- ❁ Barach AL. *Ann Intern Med.* 1938;12(4):454–81.
- ❁ Wu TD, et al. The history of pulmonary function testing. In: Kaminsky DA, Irvin CG, eds. *Pulmonary Function Testing. Principles and Practice.* Basel, Springer International Publishing, 2018;15–42.
- ❁ Yokota T, et al. *Proc Natl Acad Sci USA.* 1986;83(16):5894–5898.
- ❁ Azuma C, et al. *Nucleic Acids Res.* 1986;14(22):9149–9158.
- ❁ Pin I et al. *Thorax.* 1992;47:25–9.
- ❁ Minty A, et al. *Nature.* 1993;362(6417):248–250.
- ❁ Medzhitov R, et al. *Nature.* 1997;388(6640):394–397.
- ❁ Pavord ID, et al. *Lancet.* 1999;353(9171):2213–2214.
- ❁ Wenzel SE, et al. *Am J Respir Crit Care Med.* 1999;160(3):1001–8.
- ❁ Kirby JG, et al. *Am Rev Respir Dis.* 1987;136:379–83.
- ❁ Reche PA et al, *J Immunol.* 2001;167(1):336–343.
- ❁ Green RH, et al. *Lancet.* 2002;360(9347):1715–1721.
- ❁ Pavord I, et al. *Eur Respir Rev.* 2019;28:190054.
- ❁ Castillo JR, et al. *J Allergy Clin Immunol.* 2017;594:918–927.
- ❁ Miranda C, et al. *J Allergy Clin Immunol.* 2004;113(1):101–8.
- ❁ West EE, et al. *Drug Discov Today Dis Mech.* 2012;9(3-4):10.1016/j.ddmec.2012.09.003.
- ❁ Haldar P, et al. *Am J Respir Crit Care Med.* 2008;178(3):218–224.
- ❁ Woodruff PG, et al. *Am J Respir Crit Care Med.* 2009;180(5):388–95.
- ❁ Haldar P, et al. *N Engl J Med.* 2009;360:973-84.
- ❁ Moore WC, et al. *Am J Respir Crit Care Med.* 2010;181(4):315–323.
- ❁ Halim T. *Int Immunol.* 2016;28(1):13–22.
- ❁ Porpodis K, et al. *J Pers Med.* 2022;12:1093.
- ❁ Lötval J, et al. *J Allergy Clin Immunol.* 2011;127(2):355–360.



References (2/2)

- ❁ Baines KJ, et al. *J Allergy Clin Immunol.* 2011;127:153 –160.
- ❁ Wenzel SE. *Nat Med.* 2012;18:716–725.
- ❁ Price DB, et al. *Lancet Respir Med.* 2015;3(11):849 –858.
- ❁ Bafadhel M, et al. *Am J Respir Crit Care Med.* 2011;184:662 –71.
- ❁ Bafadhel M, et al. *Am J Respir Crit Care Med.* 2012;186:48 –55.
- ❁ Bafadhel M, et al. *Eur Respir J.* 2014;44:789 –91.
- ❁ Agusti A, et al. *Eur Respir J.* 2016;47:410 –419.
- ❁ Hunninghake GM, et al. *Allergy.* 2010; 65:1566 –1575.
- ❁ Moffatt MF, et al. *N Engl J Med.* 2010; 363:1211 –1221.
- ❁ Torgerson DG, et al. *Nat Genet.* 2011; 43:887 –892.
- ❁ Holgate ST. *Immunol Rev.* 2011;242:205 –219.
- ❁ Heijink IH, et al. *Clin Exp Allergy.* 2014;44(5):620 –630.
- ❁ Li X, et al. *Allergy.* 2015;70(10):1309 –1318.
- ❁ Plasschaert LW, et al. *Nature.* 2018;560(7718):377 –38.
- ❁ Couillard S, et al. *Am J Respir Crit Care Med.* 2021;204:731 –4.
- ❁ Couillard S, et al. *ERJ Open Res.* 2021;8(1):00570 –2021.
- ❁ Couillard S, et al. *Thorax.* 2022;77(2):199 –202.
- ❁ Couillard S, et al. *Respirology.* 2022;27:573 –574.
- ❁ Heijink IH, et al. *Eur J Allergy Clin Immunol.* 2020;75(8):1902 –1917.